NT Pro-BNP can be used as a Risk Predictor of Clinical Atrial Fibrillation with or without Left Atrial Enlargement

Zhao X¹, Li H², Liu C¹, Ren Y³ and Sun C*⁴
¹Health Science Center, Xi’an Jiaotong University, Shaanxi Province, P.R. China
²Department of Rehabilitation and Treatment, The First Affiliated Hospital of Xi’an Jiaotong University, Shaanxi Province, P.R. China
³Medical Science Center, Yan’an University, Shaanxi Province, P.R. China
⁴Cardiovascular Department, The First Affiliated Hospital of Xi’an Jiaotong University, Shaanxi Province, P.R. China

*Corresponding author: Sun C, Doctoral Supervisor, Cardiovascular Department, The First Affiliated Hospital of Xi’an Jiaotong University, Shaanxi Province, P.R. China, Tel: + 8618191273192; E-mail: chaofengxju@163.com

Received: May 17, 2019; Accepted: May 29, 2019; Published: June 06, 2019

Copyright: © 2019 Zhao X, et al. This is an open-access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: NT Pro-BNP is a blood marker secreted from myocardial. The main stimulus for cardiac NT Pro-BNP secretion is myocardial stretch. NT Pro-BNP is a significant risk factor for stroke of cardiac insufficiency and pulmonary embolism. Patients with normal levels of NT-pro-BNP have low risks for death. So does atrial stretch

Retraction note: Publisher took the decision to retract the article from the journal.